Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old

NCT04918771 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

435

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Respiratory Viral Infection

Interventions

DRUG: Raphamin
DRUG: Placebo

Sponsor

Materia Medica Holding